bimzelx solution
ucb canada inc - bimÉkizumab - solution - 160mg - bimÉkizumab 160mg
bimzelx solution
ucb canada inc - bimÉkizumab - solution - 160mg - bimÉkizumab 160mg
skyrizi 75 mg lnjektionslösung in einer fertigspritze
abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml. tela cum: alcohol isopropylicus. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika
skyrizi 150 mg lnjektionslösung in einer fertigspritze
abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika
skyrizi 150mg solution injectable en stylo prérempli
abbvie ag - risankizumabum - solution injectable en stylo prérempli - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika
tremfya solution
janssen inc - guselkumab - solution - 100mg - guselkumab 100mg - misc. skin and mucous membrane agents
tremfya one-press solution
janssen inc - guselkumab - solution - 100mg - guselkumab 100mg - misc. skin and mucous membrane agents
bimzelx 160 mg solution injectable en seringue préremplie
ucb-pharma sa - bimekizumabum - solution injectable en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika
bimzelx 160 mg solution injectable en stylo prérempli
ucb-pharma sa - bimekizumabum - solution injectable en stylo prérempli - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika
tremfya
janssen-cilag international nv - guselkumab - psoriasis - immunosuppresseurs - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.